Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNK2 | Q07912 | 8/20 | 0.61 |
| ▸ | RAF1 | P04049 | 1/20 | 0.44 |
| ▸ | SRC | P12931 | 1/20 | 0.44 |
| ▸ | FGFR4 | P22455 | 7/20 | 0.43 |
| ▸ | FGFR1 | P11362 | 4/20 | 0.43 |
| ▸ | FGFR3 | P22607 | 2/20 | 0.43 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.43 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.42 |
| ▸ | BTK | Q06187 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18099743 | 0.90 | TNK2 (0.58) | TNK2FGFR4FGFR1FGFR3FGFR2 | |
| SCHEMBL18345263 | 0.89 | TNK2 (0.60) | TNK2FGFR4FGFR1FGFR3FGFR2 | |
| SCHEMBL16748869 | 0.89 | TNK2 (0.60) | TNK2FGFR4FGFR1FGFR3FGFR2 | |
| SCHEMBL18099750 | 0.88 | TNK2 (0.51) | TNK2GPR119KDM4EMAPTTHRB | |
| SCHEMBL20392997 | 0.83 | TNK2 (0.51) | TNK2BTK | |
| SCHEMBL26791421 | 0.82 | TNK2 (0.59) | TNK2RAF1SRCFGFR4FGFR1 | |
| SCHEMBL26820282 | 0.82 | TNK2 (0.59) | TNK2RAF1SRCFGFR4FGFR1 | |
| SCHEMBL14630461 | 0.80 | IGF1R (0.51) | TNK2 | |
| SCHEMBL14630227 | 0.80 | FGFR4 (0.49) | TNK2RAF1SRCFGFR4FGFR1 | |
| SCHEMBL27188434 | 0.80 | FGFR4 (0.49) | TNK2RAF1SRCFGFR4FGFR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9822120-B2 | Protein kinase inhibitors | PHARMASCIENCE INC. (CA) | 2017-11-21 | — | — | US | disclosed |
| US-9822120-B2 | Protein kinase inhibitors | PHARMASCIENCE INC. (CA) | 2017-11-21 | — | — | US | disclosed |
| US-20160280711-A1 | Protein Kinase Inhibitors | PHARMASCIENCE INC. (CA) | 2016-09-29 | — | — | US | disclosed |
| US-20160280711-A1 | Protein Kinase Inhibitors | PHARMASCIENCE INC. (CA) | 2016-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160280711-A1 | Protein Kinase Inhibitors | TEC, LCK, SRC | TNK2 43/4885RAF1 54/4885SRC 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.